When was Q Chip founded?

Q Chip was founded in 2003 and raised its 1st funding round 7 years after it was founded.

Where is Q Chip located?

Q Chip is headquartered in Cardiff, United Kingdom.

How many employees does Q Chip have?

As of Dec 31, 2021, the latest employee count at Q Chip is 13.

Is Q Chip a funded company?

Q Chip is a funded company, having raised a total of $14.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Sep 18, 2010.

When was the latest funding round of Q Chip?

Q Chip's latest funding was a $***** Series C round on May 20, 2011, with participation from 5 investors. Its primary sector is Life Sciences Platforms and Tools. In United Kingdom, the Life Sciences Platforms and Tools sector has seen $98.8M in funding in 2026 to date.

Where does Q Chip rank among its competitors?

Q Chip ranks 515th amongst 1986 active competitors, of which 463 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Q Chip?

Q Chip's top competitors include MannKind Corp, Synthego and Sutro Biopharma. Among them, Antheia secured the most recent funding round in January, 2026.

Q Chip - 2026 Company Profile, Team, Funding, Competitors & Financials

Q Chip is an acquired company based in Cardiff (United Kingdom), founded in 2003 by David Barrow. It operates as a Drug delivery company delivering a tuneable sustained release technology platform for peptide and small-molecule therapeutics.. Q Chip has raised $14.2M in funding from Limburg Ventures and LIOF. The company has 1986 active competitors, including 463 funded and 365 that have exited. Its top competitors include companies like MannKind Corp, Synthego and Sutro Biopharma.

Company Details

Q Chip is a drug delivery company with expertise in the application of fluidic droplet systems (including microfluidic and piezo actuator-based platforms). Focus is on formulating monodisperse microspheres for the controlled release of therapeutics. The Q-Sphera Microsphere production platform was developed in response to the limitations of current microsphere manufacturing methods and delivers consistent, reproducible and highly efficient cGMP-compliant production of microspheres whilst providing control over release kinetics. Q Chip also administer, sustained release products in development for acromegaly (Q-Octreotide) and diabetes (Q-Exenatide) which offer long duration of action with defined release profiles. Acquired by Midatech Pharma in December, 2014.

Website: q-chip.com
Social

Key Metrics

Founded Year

2003

Location

Cardiff, United Kingdom

Stage

Acquired

Total Funding

$14.2M in 2 rounds

Latest Funding Round

Series C, May 20, 2011, $*****

Investors

Limburg Ventures & 4 more

Ranked

515^th among 1986 active competitors

Employee Count

13 as on Dec 31, 2021

Similar Companies

MannKind Corp & 2715 more

Exit Details

Acquired by Midatech (Dec 08, 2014)

View Q Chip's full profile

Q Chip is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Midatech Pharma (wales) Limited CIN: 4929486 , Germany, Active	Oct 09, 2003	-	13 (As on Dec 31, 2021)

Q Chip got acquired by Midatech on Dec 08, 2014. It was facilitated by Panmure Gordon, Brown Rudnick, BDO and 1 more.

Click here to take a look at Q Chip's acquisition in detail

Q Chip has raised a total funding of $14.2M over 2 rounds. Its first funding round was on Sep 18, 2010. Its latest funding round was a Series C round on May 20, 2011 for $*****. 5 investors participated in its latest round. Q Chip has 5 institutional investors.

Here is the list of recent funding rounds of Q Chip:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 20, 2011	2125607	Series C	2222192	5315449	2330544	2226413
Sep 18, 2010	3107987	Series B	2260440	8627782	5688747	Finance Wales

Access funding benchmarks and valuations. Sign up today!

View details of Q Chip's funding rounds and investors

The founders of Q Chip is David Barrow.

Here are the details of Q Chip's key team members:

David Barrow: Former Co-Founder of Q Chip.

View details of Q Chip's Founder profiles and Board Members

Q Chip's employee count trend

Q Chip has 13 employees as of Dec 21. The total employee count is 13.0% lower than what it was in Dec 20. Here is Q Chip's employee count trend over the years:

Uncover Q Chip's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Q Chip include MannKind Corp, Synthego and Sutro Biopharma. Here is the list of Top 10 competitors of Q Chip, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	72/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
3rd	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
4th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Longitude Capital & 6 others	69/100
5th	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	68/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, New Enterprise Associates & 14 others	67/100
7th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Logos & 19 others	67/100
8th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	67/100
9th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
10th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Third Rock Ventures, Pfizer Venture Investments ... & 8 others	66/100
515th	Q Chip 2003, Cardiff (United Kingdom), Acquired	Drug delivery company delivering a tuneable sustained release technology platform for peptide and small-molecule therapeutics.	$14.2M	Disruptive Capital, LIOF & 3 others	34/100